VIR (31) ALVO (58) BCRX (78) VCEL (67) ⌘ Pro Terminal →

Mesoblast Limited (MESO) — RQD Stock Rating Cockpit

$15.67 +17.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Mesoblast Limited (MESO) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $2.04B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MESO)Realized 20D OHLCV Swing Band: ±6.8%

RSI-14 MOMENTUMBULLISH MOMENTUM

58.630 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE39% OF RANGE

L: $12$15.67H: $22

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 22 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on MESO

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (58)

22/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like MESO

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (MESO Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MESO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.00%▼ DESCENDING CHANNEL

2026-10-30O $15.38H $15.69L $14.84C $15.67VOL 376.0K

RES: $16.78SUP: $11.54SMA50: $14.93SMA200: $15.41

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MESO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MESO Butterfly Map → + Track MESO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MESO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MESO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MESO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MESO)

Health Care Rank #202 of 1016 ⚔️ VIR vs MESO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MESO vs. VIR, ALVO, BCRX, VCEL)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Mesoblast Limited (MESO) ranks #202 by composite RQD confidence (60/100, grade C-) and #260 by equity capitalization ($2.04B). Within this direct 5-issuer industry benchmark cohort, BCRX leads on earnings valuation at 8.3x trailing P/E, while BCRX leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. BCRX currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with MESO at 60/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MESO ACTIVE Mesoblast Limited	C-	60/100	—	—	—	+17.03%	$2.04B	Benchmark Subject
VIR Vir Biotechnology Inc.	E	31/100	—	96.0%	-35.0%	-1.51%	$2.01B	/vir-vs-meso →
ALVO Alvotech	D+	58/100	—	—	—	-1.01%	$1.91B	/alvo-vs-meso →
BCRX BioCryst Pharmaceuticals Inc.	B+	78/100	8.3x	—	85.0%	+1.79%	$2.18B	/bcrx-vs-meso →
VCEL Vericel Corporation	C+	67/100	133.0x	74.4%	3.4%	+4.43%	$2.20B	/vcel-vs-meso →

2. MESO Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Mesoblast Limited (MESO) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $2.04B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. MESO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MESO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Mesoblast Limited (NASDAQ: MESO) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $15.67 (+17.03% 1D, market cap $2.04B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, MESO ranks #202 in composite RQD confidence.

How does MESO compare to VIR and ALVO in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MESO carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, VIR (Vir Biotechnology Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.01B) and ALVO (Alvotech) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.91B). Among the 5-stock peer group, BCRX leads on earnings multiple (8.3x) while BCRX leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MESO?

For Mesoblast Limited (MESO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #202 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MESO trading relative to its 50-day, 200-day, and 52-week technical levels?

MESO last traded at $15.67 (+17.03% on volume of 698,557 shares), positioning the stock +4.96% above its 50-day simple moving average ($14.93) and +1.69% above its 200-day simple moving average ($15.41). Across its 52-week range of $11.89 to $21.50, MESO sits at the 39.3% percentile with a 14-day RSI of 58.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.8% ($14.60 to $16.74).

MESO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell MESO stock right now?

Mesoblast Limited (MESO) currently earns a Roarable Rating of C- (Hold — HOLD) with 60/100 RQD Confidence. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.

What is MESO's 12-month price target and RQD AI Jury consensus?

MESO's 12-month base price target is $15.81 (range $12.33 to $22.57), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: MESO RQD Cockpit MESO 12M Forecast MESO Earnings & Move MESO Dividends & DRIP MESO Insiders & 13F MESO Whale Options MESO Profit Sankey MESO News & Why